# Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia

> **NCT02882282** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 15 (actual)

## Conditions studied

- Oral Cavity Carcinoma
- Oral Intraepithelial Neoplasia

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Patient Observation
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02882282
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-14
- **Primary completion:** 2025-07-14
- **Final completion:** 2025-07-14
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02882282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02882282, "Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02882282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*